| Symbol | MNPR |
|---|---|
| Name | MONOPAR THERAPEUTICS |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL 60091 |
| Telephone | 8473880349 |
| Fax | — |
| — | |
| Website | https://www.monopartx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001645469 |
| Description | Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The companys pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Additional info from NASDAQ: |
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD– The Liver Meeting® 2026
Read moreMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
Read moreNew Form SCHEDULE 13G/A - Monopar Therapeutics <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0002060757-26-000047 <b>Size:</b> 13 KB
Read more(90% Positive) MONOPAR THERAPEUTICS (MNPR) Announces Clinical Development Update
Read moreMonopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Read moreNew Form SCHEDULE 13G/A - Monopar Therapeutics <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004969 <b>Size:</b> 13 KB
Read moreNew Form S-8 POS - Monopar Therapeutics <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001437749-26-024132 <b>Size:</b> 108 KB
Read moreNew Form S-8 POS - Monopar Therapeutics <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001437749-26-024131 <b>Size:</b> 108 KB
Read moreNew Form S-8 POS - Monopar Therapeutics <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001437749-26-024130 <b>Size:</b> 108 KB
Read moreNew Form S-8 - Monopar Therapeutics <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001437749-26-024127 <b>Size:</b> 242 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06980506 | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor … | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06980519 | MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor… | — | Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-10-08 | 2027-01-01 | ClinicalTrials.gov |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid … | Phase1 | Solid Tumor, Adult | Recruiting | 2024-05-30 | 2026-04-01 | ClinicalTrials.gov |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Phase1 | Advanced Soft-tissue Sarcoma | Terminated | 2021-09-22 | 2024-05-13 | ClinicalTrials.gov |
| NCT04648020 | Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral … | Phase2 | Chemoradiotherapy-Induced Severe Oral Mucositis | Terminated | 2021-02-11 | 2023-05-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | Other | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Camsirubicin | Other | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| MNPR-101-PCTA-177Lu | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06617169 |
| MNPR-101-PCTA-177Lu | Other | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | Other | Preclinical | Cancer | AVAILABLE | NCT06980506 |
| PET/CT Diagnostic Imaging | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-DFO*-89Zr | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| MNPR-101-PCTA-177Lu | BIOLOGICAL | Preclinical | Cancer | AVAILABLE | NCT06980519 |
| MNPR-101-DFO*-89Zr | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06337084 |
| Camsirubicin | DRUG | Phase PHASE1 | Advanced Soft-tissue Sarcoma | TERMINATED | NCT05043649 |
| Placebo Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |
| Clonidine HCl Mucoadhesive Buccal Tablet | DRUG | Phase PHASE2 | Chemoradiotherapy-Induced Severe Oral Mucositis | TERMINATED | NCT04648020 |